The Allen Institute Launches Brain Health Accelerator
A major new collaborative initiative is underway in Seattle, aiming to develop genetic therapies for some of the most devastating brain disorders. The Brain Health accelerator, launched by the Allen Institute, will focus on conditions including Alzheimer's, Parkinson's, ALS, and Huntington's disease.
"We now have a complete description of the types of cells that make up the brain, and also the genetic underpinnings of their properties. This foundation then lets you study disease." – Ed Lein, Director of Brain Health Programs, Allen Institute
A New Approach to Brain Disease
The accelerator is an outgrowth of the BRAIN Initiative, announced by President Obama in 2013. Its core mission is to develop genetic therapies—including both gene editing and traditional gene therapy—to control specific gene activity in the brain.
Ed Lein noted that these therapies allow for precise targeting of brain disorders, offering a level of specificity that was previously unattainable. John Ngai, director of the NIH's BRAIN Initiative, described the pace of progress as "faster than expected," stating the advances are "beyond his imagination."
Hope for Huntington's Disease
Jeff Carroll, a researcher who carries the Huntington's gene, has joined the accelerator after working at the University of Washington. He explained that Huntington's is caused by a single gene that produces toxic protein levels, making it a prime target for this approach.
"It's difficult to do the scale of research that you need with a team of five or six or even 10 people. The hundreds of people they have here at the Allen Institute [allow for] an entirely different approach to science." – Jeff Carroll, Researcher
Carroll noted that genetic therapies have already succeeded in treating spinal muscular atrophy, with children who previously died in infancy now attending high school. He stated that the goal for Huntington's is to "eliminate that gene."
The Allen Institute's Foundation
Founded in 2003 by Paul and Jody Allen, the institute has long been focused on developing technologies to characterize and map brain cells. Scientists have already studied how Alzheimer's disease affects specific neuron types, building a critical foundation for this new work.
Crucially, the institute makes its databases publicly available, allowing researchers around the world to contribute to therapy development. This open-science model is designed to accelerate progress against some of humanity's most challenging diseases.